ClinicalTrials.gg
RecruitingNCT07939854Updated Nov 16, 2026

Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage

An interventional study of Neuronavigation-Guided Stereotactic Hematoma Aspiration and Tenecteplase in Primary Pontine Hemorrhage, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2026, registered Nov 2026).
  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.

02

Conditions studied

  • Primary Pontine Hemorrhage
03

In context

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 493 studies on the registry; 297 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and \<80 years.
  • Diagnostic CT completed within 24 hours after symptom onset. Patients with unknown onset time will be excluded. For patients with symptoms first noted during sleep, the time last known well will be considered the onset time.
  • Acute primary brainstem hemorrhage confirmed by head CT, with the predominant hematoma location in the pons (>50% of the hematoma located in the pons); hematoma volume 5-10 mL as measured by the ABC/2 method. The hematoma must be located within the brainstem parenchyma rather than primarily within the ventricles, although extension into the third or fourth ventricle is permitted. For unilateral hemorrhage, a hematoma volume of 3-5 mL is permitted.
  • A repeat CT scan performed 6 hours after symptom onset confirms that the hematoma volume remains within the eligibility range.
  • Glasgow Coma Scale (GCS) score ≥5 and \<12 at enrollment.
  • Randomization initiated between 6 and 12 hours after the diagnostic CT.
  • Systolic blood pressure (SBP) \<180 mmHg maintained during the 6 hours immediately before randomization.
  • Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  • Voluntary participation in the study with written provided by the participant or legally authorized representative, as applicable.

Exclusion criteria

Exclusion Criteria:

  • Supratentorial hemorrhage, posterior fossa hemorrhage, or cerebellar hemorrhage.
  • Signs of extremely severe disease, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, or loss of spontaneous respiration.
  • The predominant portion of the hematoma involves the midbrain or medulla.
  • Brainstem hemorrhage secondary to another cerebrovascular or neurological disorder, including cerebral vascular malformation, intracranial aneurysm, other cerebrovascular abnormalities, moyamoya disease, hemorrhagic transformation of ischemic stroke, or hemorrhage related to a neurological tumor.
  • Unstable infratentorial space-occupying lesion, transtentorial herniation, or foramen magnum herniation.
  • Previous history of brainstem hemorrhage.
  • Irreversible brainstem dysfunction, defined as a GCS score ≤4 or ≥12.
  • An indication for craniotomy because of either: (a) progressive deterioration of consciousness; or (b) preoperative cerebral herniation, including signs associated with foramen magnum herniation or uncal herniation.
  • CT evidence indicating a high risk of rebleeding, including a spot sign.
  • count \<100,000/mL or (INR) >1.4.
  • Any irreversible coagulation disorder, including hemophilia or von Willebrand disease, use of anticoagulants such as warfarin, or a known disorder of clot formation, including a hypercoagulable state.
  • Inability to maintain INR ≤1.4 despite treatment with short- or long-acting hemostatic agents, including recombinant factor VIIa, fresh frozen plasma, or vitamin K.
  • Requirement for long-term anticoagulation. Patients who can undergo temporary reversal of anticoagulation but cannot discontinue warfarin or other anticoagulants for the subsequent 30 days will be excluded.
  • Use within 1 week before symptom onset of dabigatran, apixaban, rivaroxaban, tirofiban, ticagrelor, cilostazol, or clopidogrel.
  • Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary systems, or respiratory tract bleeding.
  • Superficial bleeding at a vascular access site (e.g., venous cutdown or arterial puncture) or surgical site.
  • Positive urine or serum pregnancy test in a premenopausal woman without documented surgical sterilization.
  • Known to tenecteplase.
  • Previous participation in this study with completed randomization.
  • Concurrent participation in another interventional medical study or clinical trial. Participation in an observational study, natural history study, or epidemiological study without an interventional component is permitted.
  • Before randomization, the participant is not expected to survive through the Day 365 follow-up, or has requested do-not-resuscitate (DNR) or do-not-intubate (DNI) status.
  • Any serious concomitant disease expected to substantially affect prognosis, including severe hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune, or hematologic disease.
  • Presence of a mechanical prosthetic heart valve. A bioprosthetic heart valve is permitted.
  • Known embolic risk, including a history of left-sided intracardiac thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
  • Any condition requiring immediate emergency treatment outside the study protocol, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, loss of spontaneous respiration, signs of cerebral herniation, progressive respiratory or circulatory failure, or a multidisciplinary determination that immediate craniotomy for hematoma evacuation, decompressive craniectomy, emergency external ventricular drainage, or other emergency treatment is required. Study screening and randomization must not delay necessary emergency treatment.
  • The participant requests conservative treatment or conventional open microsurgical treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Stereotactic Aspiration Combined With Tenecteplase

    Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment.

    Procedure: Neuronavigation-Guided Stereotactic Hematoma Aspiration · Drug: Tenecteplase · Other: Standard Medical Treatment

  • Active comparator
    Standard Medical Treatment

    Other: Standard Medical Treatment

Interventions

  • ProcedureNeuronavigation-Guided Stereotactic Hematoma Aspiration

    Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization.

  • Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.

    Also known as: rhTNK-tPA

  • OtherStandard Medical Treatment

    Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With GCS Score >8

    Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days.

    Time frame: 90 days after randomization

  2. All-Cause Mortality

    Proportion of participants who die from any cause within 30 days after randomization.

    Time frame: Within 30 days after randomization.

Secondary outcomes

  1. 7-Day All-Cause Mortality

    Time frame: Within 7 days

  2. Symptomatic Rebleeding

    Time frame: Within 72 hours after tenecteplase administration

  3. Intracranial Bacterial Infection

    Time frame: Within 30 days

  4. Serious Adverse Events (SAEs)

    Time frame: Within 30 days

  5. Adverse Events (AEs)

    Time frame: Within 30 days

  6. Serious Adverse Events (SAEs)

    Time frame: Within 365 days

  7. Adverse Events (AEs)

    Time frame: Within 365 days

  8. Proportion With GCS Increase ≥3 Points

    Time frame: 30 days

  9. Proportion With Recovery of Consciousness

    Time frame: 30 days

  10. Proportion With mRS 0-3

    Time frame: 90 days

  11. Proportion With mRS 0-3

    Time frame: 365 days

  12. Change in GCS Score Over Time

    Time frame: From baseline through 90 days after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939854
Responsible party
Dr. Yong Cao (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Apr 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Yong Cao
Contact
caoyong@bjth.org
+86 13601362306

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion